EPLIN Expression in Gastric Cancer and Impact on Prognosis and Chemoresistance.

Combined analysis, designed to give a broader overview and combat low sample numbers in such groups and looking at EPLIN expression in BorrmannI + BorrmannII groups compared to BorrmannIII + BorrmannIV groups demonstrated a generally higher level of EPLIN expression in the combined BorrmannI + BorrmannII stage tumours compared to the combined BorrmannIII + BorrmannIV stage tumours groups, with near significance observed ( p = 0.071).

also in 505 other papers

Longer OS rates were seen in patients with high EPLIN expression (median = 23.367 months; 95% cl: 8.199–38.535 months) compared to those with low EPLIN expression (median = 20.5 months; 95% cl: 14.306–26.694 months), but it did not reach statistical significance ( Figure 5 A).

also in 111,027 other papers